Comprehensive analysis of the oncogenic roles of vascular endothelial growth factors and their receptors in stomach adenocarcinoma.

Bioinformatics Prognosis Stomach adenocarcinoma Vascular endothelial growth factor receptors Vascular endothelial growth factors

Journal

Heliyon

ISSN: 2405-8440

Titre abrégé: Heliyon

Pays: England

ID NLM: 101672560

Informations de publication

Date de publication:
Jul 2023

Historique:

received: 18 02 2023

revised: 19 06 2023

accepted: 26 06 2023

medline: 14 7 2023

pubmed: 14 7 2023

entrez: 14 7 2023

Statut: epublish

Résumé

Vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) play complicated oncogenic roles in multiple tumors by initiating and promoting tumor angiogenesis and lymphangiogenesis. The main goal of our study was to comprehensively investigate the oncogenic roles of VEGFs and VEGFRs in stomach adenocarcinoma (STAD). The present study applied multiple bioinformatic tools to comprehensively explore the expression levels, prognostic values, genetic alterations and immune infiltrations of VEGFs and VEGFRs in STAD patients. We found that Our study systematically explored the transcriptome profiles and distinct prognostic values of VEGFs and their receptors in STAD and contributed to a better understanding of the oncogenic roles of VEGF/VEGFR members in STAD.

Sections du résumé

Background UNASSIGNED

Methods UNASSIGNED

The present study applied multiple bioinformatic tools to comprehensively explore the expression levels, prognostic values, genetic alterations and immune infiltrations of VEGFs and VEGFRs in STAD patients.

Results UNASSIGNED

We found that

Conclusion UNASSIGNED

Our study systematically explored the transcriptome profiles and distinct prognostic values of VEGFs and their receptors in STAD and contributed to a better understanding of the oncogenic roles of VEGF/VEGFR members in STAD.

Identifiants

DOI: 10.1016/j.heliyon.2023.e17687 PMID: 37449140 PMC: PMC10336736

pubmed: 37449140

doi: 10.1016/j.heliyon.2023.e17687

pii: S2405-8440(23)04895-8

pmc: PMC10336736

doi:

Types de publication

Journal Article

Langues

eng

Pagination

e17687

Informations de copyright

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Cancer Res. 2017 Nov 1;77(21):e108-e110

pubmed: 29092952

J Exp Clin Cancer Res. 2020 Oct 20;39(1):221

pubmed: 33081836

Biomark Med. 2021 May;15(7):481-488

pubmed: 33856262

Int J Mol Med. 2011 Nov;28(5):761-8

pubmed: 21805024

Front Mol Biosci. 2020 Nov 02;7:573619

pubmed: 33240929

Expert Rev Anticancer Ther. 2011 Apr;11(4):541-9

pubmed: 21504321

Clin Chim Acta. 2017 Nov;474:114-119

pubmed: 28939099

Growth Factors. 2001;19(1):49-59

pubmed: 11678209

Yonsei Med J. 2013 Mar 1;54(2):374-80

pubmed: 23364970

Neoplasia. 2004 Jan-Feb;6(1):1-6

pubmed: 15068665

Am J Chin Med. 2019;47(4):865-878

pubmed: 31091971

Mol Biol Rep. 2012 Oct;39(10):9473-84

pubmed: 22729879

Rep Biochem Mol Biol. 2019 Oct;8(3):244-252

pubmed: 32274396

Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419861600

pubmed: 31266378

J Biochem. 2013 Jan;153(1):13-9

pubmed: 23172303

World J Gastroenterol. 2004 Feb 1;10(3):352-5

pubmed: 14760756

PLoS One. 2011;6(10):e23208

pubmed: 22028766

Int J Cancer. 2014 Oct 1;135(7):1553-63

pubmed: 24585459

Clin Sci (Lond). 2005 Sep;109(3):227-41

pubmed: 16104843

Biomedicines. 2017 Jun 21;5(2):

pubmed: 28635679

Biol Pharm Bull. 2007 Apr;30(4):633-7

pubmed: 17409493

Oncotarget. 2016 Aug 2;7(31):49322-49333

pubmed: 27384994

J Hematol Oncol. 2021 Jan 12;14(1):13

pubmed: 33436042

Sci Rep. 2021 Mar 15;11(1):6047

pubmed: 33723286

Anticancer Res. 2014 Aug;34(8):3911-5

pubmed: 25075012

Cancer Lett. 2004 Sep 15;213(1):73-82

pubmed: 15312686

Rom J Morphol Embryol. 2018;59(2):455-467

pubmed: 30173249

Angiogenesis. 2017 May;20(2):185-204

pubmed: 28361267

Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):E2900-9

pubmed: 25991856

Cell Biochem Funct. 2016 Apr;34(3):173-80

pubmed: 26968576

Onco Targets Ther. 2020 Feb 13;13:1331-1341

pubmed: 32104000

Exp Cell Res. 2009 Aug 1;315(13):2154-64

pubmed: 19409892

Oncotarget. 2016 Mar 29;7(13):17074-86

pubmed: 26934554

Oxid Med Cell Longev. 2020 Oct 9;2020:3580719

pubmed: 33101586

Trends Mol Med. 2011 Jul;17(7):347-62

pubmed: 21481637

Front Oncol. 2019 Dec 12;9:1399

pubmed: 31921656

Surgery. 2009 Nov;146(5):896-905

pubmed: 19744460

Onco Targets Ther. 2019 Nov 15;12:9757-9765

pubmed: 31814734

Cancer Res. 2018 Oct 1;78(19):5600-5617

pubmed: 30111533

Asia Pac J Clin Oncol. 2019 Aug;15(4):208-217

pubmed: 31111678

Development. 2018 Jul 20;145(14):

pubmed: 30030240

Cancer Biol Ther. 2012 Mar;13(5):247-63

pubmed: 22481432

Am J Transl Res. 2014 Nov 22;6(6):756-67

pubmed: 25628786

Pharmacol Res. 2018 Oct;136:97-107

pubmed: 30170190

Cancer Sci. 2009 Feb;100(2):310-5

pubmed: 19068081

J Exp Clin Cancer Res. 2016 Jan 22;35:16

pubmed: 26795388

BMC Cancer. 2019 Feb 28;19(1):183

pubmed: 30819137

Cell. 2018 Apr 5;173(2):291-304.e6

pubmed: 29625048

J Cancer. 2021 Apr 30;12(12):3648-3659

pubmed: 33995640

Nat Genet. 2014 Jun;46(6):573-82

pubmed: 24816253

Semin Cancer Biol. 2015 Dec;35 Suppl:S224-S243

pubmed: 25600295

Cancer Chemother Pharmacol. 2019 Jun;83(6):1037-1046

pubmed: 30899983

Sci Signal. 2013 Apr 02;6(269):pl1

pubmed: 23550210

Oncology. 2002;62(2):121-7

pubmed: 11914597

Gastric Cancer. 2018 Jul;21(4):617-631

pubmed: 29243194

CA Cancer J Clin. 2018 Nov;68(6):394-424

pubmed: 30207593

Dig Dis Sci. 2019 Nov;64(11):3154-3163

pubmed: 31102128

J Immunother Cancer. 2018 Oct 11;6(1):106

pubmed: 30314524

Dis Markers. 2020 Sep 19;2020:4763492

pubmed: 33014187

Curr Treat Options Oncol. 2020 Jul 28;21(9):70

pubmed: 32725377

Oncol Rep. 2012 Dec;28(6):1935-44

pubmed: 22993103

Adv Cancer Res. 2012;114:237-67

pubmed: 22588059